References
- van der Hilst JC. Recent insights into the pathogenesis of type AA amyloidosis. SciWorld J 2011;11:641–50
- Lachmann HJ. Clinical immunology review series: an approach to the patient with a periodic fever syndrome. Clin Exp Immunol 2011;165:301–9
- Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol 2011;29:850–7
- Agarwal S, Das SK, Kumar P, Tripathi P, Mehrotra B. Amyloidosis in ankylosing spondylitis. J Clin Rheumatol 2009;15:211
- Yorioka N, Taniguchi Y, Okushin S, Amimoto D, Kataoka K, Taguchi T. Classic polyarteritis nodosa associated with renal amyloidosis. Nephron 1999;82:93–4
- Hagihara K, Nishikawa T, Sugamata Y, Song J, Isobe T, Taga T, Yoshizaki K. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 2005;10:1051–63
- Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361–71
- Hattori Y, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid 2012;19:37–40
- Inoue D, Arima H, Kawanami C, Takiuchi Y, Nagano S, Kimura T, Shimoji S, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 2010;29:1195–7
- Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, Horizono H, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009;28:1113–16